the 12 to 18 months of observation.
Circumstantiai evidence for an autoimmune etiology of psoriasis is the striking remission of psonatic lesions. which can be achieved with cyclosporine. l -l an immunosuppressive drug whose use for this pUJ'l)Ose has been limited by nephrotoxicity. hypenension. and other doserelated side effects. We repon here the use of the chemically unrelated drug. FK 506. which also inhibits T helper lymphocyte activation and the synthesis and expression of cytokines. 4 .~
METHODS
Clinical fealUres are summanzed in Table I . Amelioration ot" psonastS In four patients was Incldentaito the pnmary objective of hean lone I or livertr:m~plantallon Illiree I. The liver disease In one of the tauer patients was caused by methotrexate treatment for psoriasiS over a J)Criod of 2 years. The other three pallents had severe n:caIcitrant psoriasis that had reSisted the therapies listed in Table I . The patients were scored for their psonasis seventy using the PSOriasiS Area and Severity Index IPASIl.J The seventy of the p$Oriasis was determined lTable 2) by measuring the amount of erythema. infiltration. and desquamation usmg a scale of 0-4 10 = none. I = slight. 2 = moderate. 3 = severe. 4 the three pauents whose primary diagnosis was psonasis. biopSies terol. uric acid. blood glucose. malllesium. and other electrolytes were taken before instituting treatment. 2 weeks later. and when were monitored. A detailed repon of these parameters in a larger they were clinically free of lesions.
group of psonasis pauents IS reponed elsewhere in this sympoOral FK 506 was stancd at O.IS mg/kg twice daily in the sium. 6 nontransplant pauents and adjusted down or up according to the Development of high blood pressure was quanutated (if present! FK 506 plasma levels (measured at 12 hour trough with an by the number of antihypenensive drugs required to maintain a enzyme-linked immunoassay, or when there was clinical evidence normotensIve state. H ypcrtcalemia was treated with the minof incomplete disease control or toxicity. No other drugs were eraloconicoid f\udroconlsone acetate. Hypomagnesemia was used. The transplant recIpients were staned on 0.075 or 0.10 seen but did not require correction.
intravenous FK S06Id and convened to oral dosing when they could eat. Transplant patients aiso had prednisone anitiaily. which RESULTS was tapered to the levels shown In Table) by I February 1991.
Effect on PsonaslS
These levels have not changed substantially in the ensuing half There was a marked reduction in erythema and scale in all year.
Complete medical examinations including neurologic assessseven patients by I week and complete clinical remission ment were performed repcated1v. Re~ funcuon. serum cholcsby 3 weeks ( Table 2 ). The remission has been sustained 3324 with follow-ups of 12 to 18 months. The three patients wnose primary diagnosIs was psoriasis ( Table 2) were not given steroids or other medications. Improvement of arthritis from which they also sutfered occurred simultaneously.
Serial skin biopsies taken from the active plaques of psonasis demonstrated a rapid clearance of the inflammatory infiltrate In the dermis and the neutrophils in the stratum corneum. The etfect of FK 506 on the skin infiltrate is described elsewhere in this symposium. 7 The hyperkeratosis and epidermal acanthosis took longer to resolve / Table 2> . In these three patients. efforts to reduce FK 506 dosage resulted in beginning reappearance of the skin lesions. which promptly disappeared after returning to the prior dose.
The four patients who had organ transplants received systemic prednisone postoperauvelv. but their remiSSion persisted after lowenng (one easel or stopping the sterOIds {three cases) (Table 3) Toxicity and MetaboliC Changes FK 506 doses. plasma levels. and surveillance parameters were similar in both nontransplant and transplant patients. Temporary trembling. parathesias. and insomnia not requiring dose changes were noted in three patients. Increases of serum creatinine or BUN signaled the need for downward adjustments. and because of careful attention to dose control. there were no alarming patterns of toxicity Jt the check POints (Table 3) . While stable. the ultimate level of these measures was higher In aU patients than at the outset. Hirsutism and gingival hvperplasia sometimes associated with cyclosponne were not observed with FK 506.
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DISCUSSION
Complete remission of psoriasis induced by FK 506 was evident more qUickly than has been observed with other immunosuppressive regimens. In the nontransplant pa.
tients. the FK 506 doses and plasma levels needed to maintain remission were in the same range as required to prevent allograft rejection. Efforts to give less FK 506 to these patients resulted in reactivation of the psoriasis. In one liver recipient a dose reduction caused a minor recurrence of psoriasis rather than graft rejecllon.
Whether the reward of complete control of psoriasis will be wonh the risk of long-term therapy with this powerful drug wlil be judged with funher observations. In our psoriasis series herein reported. follow-ups have been 12 to 18 months. However. what was seen so far is encouraging. The only potentially serious side etfect was nephrotoxicity with rises an creatinine and BUN. which reo \ponded so qUickly to dose reduction that they had reached a stable although slightly elevated state at the ,urveiliance check points. No patient has had an infection. Patients with Widespread lesions toften wnh psonauc :tnhritis) that rum the quality of life have been eager to take the risk. Patients with less severe disease should be discouraged from candidacy and treated with less drastic means.
